One-year antibody durability induced by EuCorVac-19, a liposome-displayed COVID-19 receptor binding domain subunit vaccine, in healthy Korean subjects
Objective: EuCorVac-19 (ECV-19), an adjuvanted liposome-displayed receptor binding domain (RBD) COVID-19 vaccine, previously reported interim Phase 2 trial results showing induction of neutralizing antibodies 3 weeks after prime-boost immunization. The objective of this study was to determine the lo...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971223007658 |
| _version_ | 1797390559390728192 |
|---|---|
| author | Jonathan F. Lovell Kazutoyo Miura Yeong Ok Baik Chankyu Lee Jeong-Yoon Lee Young-Shin Park Ingi Hong Jung Hyuk Lee Taewoo Kim Sang Hwan Seo Jae-Ouk Kim Manki Song Chung-Jong Kim Jae-Ki Choi Jieun Kim Eun Ju Choo Jung-Hyun Choi |
| author_facet | Jonathan F. Lovell Kazutoyo Miura Yeong Ok Baik Chankyu Lee Jeong-Yoon Lee Young-Shin Park Ingi Hong Jung Hyuk Lee Taewoo Kim Sang Hwan Seo Jae-Ouk Kim Manki Song Chung-Jong Kim Jae-Ki Choi Jieun Kim Eun Ju Choo Jung-Hyun Choi |
| author_sort | Jonathan F. Lovell |
| collection | DOAJ |
| description | Objective: EuCorVac-19 (ECV-19), an adjuvanted liposome-displayed receptor binding domain (RBD) COVID-19 vaccine, previously reported interim Phase 2 trial results showing induction of neutralizing antibodies 3 weeks after prime-boost immunization. The objective of this study was to determine the longer-term antibody response of the vaccine. Methods: To assess immunogenicity 6 and 12 months after vaccination, participants in the Phase 2 trial (NCT04783311) were excluded if they: 1) withdrew, 2) reported COVID-19 infection or additional vaccination, or 3) exhibited increasing Spike (S) antibodies (representing possible non-reported infection). Following exclusions, of the 197 initial subjects, anti-S IgG antibodies and neutralizing antibodies were further assessed in 124 subjects at the 6-month timepoint, and 36 subjects at the 12-month timepoint. Results: Median anti-S antibody half-life was 52 days (interquartile range [IQR]:42-70), in the “early” period from 3 weeks to 6 months, and 130 days (IQR:97-169) in the “late” period from 6 to 12 months. There was a negative correlation between initial antibody titer and half-life. Anti-S and neutralizing antibody responses were correlated. Neutralizing antibody responses showed longer half-lives; the early period had a median half-life of 120 days (IQR:81-207), and the late period had a median half-life of 214 days (IQR:140-550). Conclusion: These data establish antibody durability of ECV-19, using a framework to analyze COVID-19 vaccine-induced antibodies during periods of high infection. |
| first_indexed | 2024-03-08T23:13:36Z |
| format | Article |
| id | doaj.art-92e258add5c642e19060a10330ea19f8 |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-03-08T23:13:36Z |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-92e258add5c642e19060a10330ea19f82023-12-15T07:22:47ZengElsevierInternational Journal of Infectious Diseases1201-97122024-01-011387380One-year antibody durability induced by EuCorVac-19, a liposome-displayed COVID-19 receptor binding domain subunit vaccine, in healthy Korean subjectsJonathan F. Lovell0Kazutoyo Miura1Yeong Ok Baik2Chankyu Lee3Jeong-Yoon Lee4Young-Shin Park5Ingi Hong6Jung Hyuk Lee7Taewoo Kim8Sang Hwan Seo9Jae-Ouk Kim10Manki Song11Chung-Jong Kim12Jae-Ki Choi13Jieun Kim14Eun Ju Choo15Jung-Hyun Choi16Department of Biomedical Engineering, University at Buffalo, Buffalo, New York, USA; Corresponding author.Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USAEubiologics, R&D Center, EuBiologics Co., Ltd., Chuncheon, KoreaEubiologics, R&D Center, EuBiologics Co., Ltd., Chuncheon, KoreaEubiologics, R&D Center, EuBiologics Co., Ltd., Chuncheon, KoreaInternational Vaccine Institute, Gwanak-gu, Seoul, KoreaInternational Vaccine Institute, Gwanak-gu, Seoul, KoreaInternational Vaccine Institute, Gwanak-gu, Seoul, KoreaInternational Vaccine Institute, Gwanak-gu, Seoul, KoreaInternational Vaccine Institute, Gwanak-gu, Seoul, KoreaInternational Vaccine Institute, Gwanak-gu, Seoul, KoreaInternational Vaccine Institute, Gwanak-gu, Seoul, KoreaDepartment of Internal Medicine, Ewha Womans University, Seoul, KoreaDepartment of Infectious Diseases, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, KoreaDepartment of Internal Medicine, Hanyang University College of Medicine, Seoul, KoreaDepartment of Infectious Diseases, Soonchunhyang University Bucheon Hospital, Bucheon, KoreaDepartment of Infectious Diseases, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, KoreaObjective: EuCorVac-19 (ECV-19), an adjuvanted liposome-displayed receptor binding domain (RBD) COVID-19 vaccine, previously reported interim Phase 2 trial results showing induction of neutralizing antibodies 3 weeks after prime-boost immunization. The objective of this study was to determine the longer-term antibody response of the vaccine. Methods: To assess immunogenicity 6 and 12 months after vaccination, participants in the Phase 2 trial (NCT04783311) were excluded if they: 1) withdrew, 2) reported COVID-19 infection or additional vaccination, or 3) exhibited increasing Spike (S) antibodies (representing possible non-reported infection). Following exclusions, of the 197 initial subjects, anti-S IgG antibodies and neutralizing antibodies were further assessed in 124 subjects at the 6-month timepoint, and 36 subjects at the 12-month timepoint. Results: Median anti-S antibody half-life was 52 days (interquartile range [IQR]:42-70), in the “early” period from 3 weeks to 6 months, and 130 days (IQR:97-169) in the “late” period from 6 to 12 months. There was a negative correlation between initial antibody titer and half-life. Anti-S and neutralizing antibody responses were correlated. Neutralizing antibody responses showed longer half-lives; the early period had a median half-life of 120 days (IQR:81-207), and the late period had a median half-life of 214 days (IQR:140-550). Conclusion: These data establish antibody durability of ECV-19, using a framework to analyze COVID-19 vaccine-induced antibodies during periods of high infection.http://www.sciencedirect.com/science/article/pii/S1201971223007658COVID-19SARS-CoV-2RBDVaccineLiposomeHumoral immunity |
| spellingShingle | Jonathan F. Lovell Kazutoyo Miura Yeong Ok Baik Chankyu Lee Jeong-Yoon Lee Young-Shin Park Ingi Hong Jung Hyuk Lee Taewoo Kim Sang Hwan Seo Jae-Ouk Kim Manki Song Chung-Jong Kim Jae-Ki Choi Jieun Kim Eun Ju Choo Jung-Hyun Choi One-year antibody durability induced by EuCorVac-19, a liposome-displayed COVID-19 receptor binding domain subunit vaccine, in healthy Korean subjects International Journal of Infectious Diseases COVID-19 SARS-CoV-2 RBD Vaccine Liposome Humoral immunity |
| title | One-year antibody durability induced by EuCorVac-19, a liposome-displayed COVID-19 receptor binding domain subunit vaccine, in healthy Korean subjects |
| title_full | One-year antibody durability induced by EuCorVac-19, a liposome-displayed COVID-19 receptor binding domain subunit vaccine, in healthy Korean subjects |
| title_fullStr | One-year antibody durability induced by EuCorVac-19, a liposome-displayed COVID-19 receptor binding domain subunit vaccine, in healthy Korean subjects |
| title_full_unstemmed | One-year antibody durability induced by EuCorVac-19, a liposome-displayed COVID-19 receptor binding domain subunit vaccine, in healthy Korean subjects |
| title_short | One-year antibody durability induced by EuCorVac-19, a liposome-displayed COVID-19 receptor binding domain subunit vaccine, in healthy Korean subjects |
| title_sort | one year antibody durability induced by eucorvac 19 a liposome displayed covid 19 receptor binding domain subunit vaccine in healthy korean subjects |
| topic | COVID-19 SARS-CoV-2 RBD Vaccine Liposome Humoral immunity |
| url | http://www.sciencedirect.com/science/article/pii/S1201971223007658 |
| work_keys_str_mv | AT jonathanflovell oneyearantibodydurabilityinducedbyeucorvac19aliposomedisplayedcovid19receptorbindingdomainsubunitvaccineinhealthykoreansubjects AT kazutoyomiura oneyearantibodydurabilityinducedbyeucorvac19aliposomedisplayedcovid19receptorbindingdomainsubunitvaccineinhealthykoreansubjects AT yeongokbaik oneyearantibodydurabilityinducedbyeucorvac19aliposomedisplayedcovid19receptorbindingdomainsubunitvaccineinhealthykoreansubjects AT chankyulee oneyearantibodydurabilityinducedbyeucorvac19aliposomedisplayedcovid19receptorbindingdomainsubunitvaccineinhealthykoreansubjects AT jeongyoonlee oneyearantibodydurabilityinducedbyeucorvac19aliposomedisplayedcovid19receptorbindingdomainsubunitvaccineinhealthykoreansubjects AT youngshinpark oneyearantibodydurabilityinducedbyeucorvac19aliposomedisplayedcovid19receptorbindingdomainsubunitvaccineinhealthykoreansubjects AT ingihong oneyearantibodydurabilityinducedbyeucorvac19aliposomedisplayedcovid19receptorbindingdomainsubunitvaccineinhealthykoreansubjects AT junghyuklee oneyearantibodydurabilityinducedbyeucorvac19aliposomedisplayedcovid19receptorbindingdomainsubunitvaccineinhealthykoreansubjects AT taewookim oneyearantibodydurabilityinducedbyeucorvac19aliposomedisplayedcovid19receptorbindingdomainsubunitvaccineinhealthykoreansubjects AT sanghwanseo oneyearantibodydurabilityinducedbyeucorvac19aliposomedisplayedcovid19receptorbindingdomainsubunitvaccineinhealthykoreansubjects AT jaeoukkim oneyearantibodydurabilityinducedbyeucorvac19aliposomedisplayedcovid19receptorbindingdomainsubunitvaccineinhealthykoreansubjects AT mankisong oneyearantibodydurabilityinducedbyeucorvac19aliposomedisplayedcovid19receptorbindingdomainsubunitvaccineinhealthykoreansubjects AT chungjongkim oneyearantibodydurabilityinducedbyeucorvac19aliposomedisplayedcovid19receptorbindingdomainsubunitvaccineinhealthykoreansubjects AT jaekichoi oneyearantibodydurabilityinducedbyeucorvac19aliposomedisplayedcovid19receptorbindingdomainsubunitvaccineinhealthykoreansubjects AT jieunkim oneyearantibodydurabilityinducedbyeucorvac19aliposomedisplayedcovid19receptorbindingdomainsubunitvaccineinhealthykoreansubjects AT eunjuchoo oneyearantibodydurabilityinducedbyeucorvac19aliposomedisplayedcovid19receptorbindingdomainsubunitvaccineinhealthykoreansubjects AT junghyunchoi oneyearantibodydurabilityinducedbyeucorvac19aliposomedisplayedcovid19receptorbindingdomainsubunitvaccineinhealthykoreansubjects |